On Friday, Royal Dutch Shell plc (ADR) (NYSE:RDS.B)’s shares declined -1.70% to $58.85.
On Thursday, July 30, 2015 at 07.00 BST (08.00 CEST and 02.00 EDT) Royal Dutch Shell plc (RDS-B) will release its second quarter results and second quarter interim dividend declarement for 2015.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids. It also converts natural gas to liquids to provide fuels and other products; markets and trades natural gas; extracts bitumen from mined oil sands and converts it to synthetic crude oil; and generates electricity from wind energy.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s shares dropped -2.49% to $12.14.
Ironwood Pharmaceuticals, Inc. (IRWD) declared the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022 (the Notes). The Notes are being offered and sold to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended. Ironwood has also granted the initial purchasers of the Notes an option to purchase up to an additional $45 million aggregate principal amount of the Notes solely to cover over-allotments.
The Notes will bear cash interest at a rate of 2.25%, payable on June 15 and December 15 of each year, startning on December 15, 2015. The Notes will not be redeemable prior to maturity. The Notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Ironwood Class A common stock, or a combination of cash and shares of Ironwood’s Class A common stock, at Ironwood’s election. The initial conversion rate for the Notes is 60.3209 shares of Ironwood’s Class A common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of about $16.58 per share of Ironwood’s Class A common stock, representing an about 35% conversion premium based on the last stated sale price of Ironwood’s Class A common stock of $12.28 per share on June 9, 2015.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnershipagreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau.
At the end of Friday’s trade, Aon Plc (NYSE:AON)‘s shares dipped -0.93% to $102.23.
Aon Plc (NYSE:AON) released results of a new survey that finds Canadian employers face difficulty evaluating the impact of Employee Assistance Programs (EAPs). A successful EAP can enhance engagement and productivity by assisting employees and their family members resolve problems affecting their well-being, but the survey found that many Canadian employers are unsure of how an EAP advances their overall organizational objectives.
Aon Hewitt’s survey of more than 130 organizations gauged employers’ views on how the success of an EAP or an Employee and Family Assistance Program (EFAP) is evaluated and how well these programs align with broader business objectives. Widely offered by Canadian employers, EAPs provide counseling and support services to employees and their families facing life challenges such as marital breakdown, addiction, illness, psychological issues, or difficulties related to balancing work and non-work activities, such as childcare and eldercare. When implemented as part of an organization’s people and risk strategy, these programs can have a number of positive outcomes, counting higher employee engagement, higher productivity and reduced costs related to absence and illness.
Aon plc provides risk administration services, insurance and reinsurance brokerage, and human resource consulting and outsourcing services worldwide. It operates through two segments, Risk Solutions and HR Solutions. The Risk Solutions segment offers retail brokerage services, counting affinity products, managing general underwriting, placement, captive administration services, and data and analytics; risk administration solutions for property liability, general liability, professional liability, directors’ and officers’ liability, workers’ compensation, and various healthcare products; and health and benefits consulting services comprising structuring, funding, and administering employee benefit programs. This segment also provides advisory services to technology, financial services, agribusiness, aviation, construction, health care, energy, and other industries.
Xilinx, Inc. (NASDAQ:XLNX), ended its Friday’s trading session with -1.21% loss, and closed at $46.65.
Xilinx, Inc. (XLNX) will be demonstrating its ‘Any Media over Any Network’ solutions optimized for the Pro A/V industry at InfoComm 2015. Xilinx will showcase its All Programmable IP for video processing, video connectivity and Codecs that support 4K and beyond at InfoComm 2015, June 17-19, at the Orlando Convention Center.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
